Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism
Authors:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2014 (1) , 768540
Abstract
Total alkaloids in Rubus aleaefolius Poir (TARAP) is a folk medicinal herb that has been used clinically in China to treat nonalcoholic fatty liver disease (NAFLD) for many years. However, the mechanism of its anti‐NAFLD effect is largely unknown. In this study, we developed a NAFLD rat model by supplying a modified high‐fat diet (mHFD) ad libitum for 8 weeks and evaluated the therapeutic effect of TARAP in NAFLD rats as well as the underlying molecular mechanism. We found that TARAP could reduce the serum triglycerides (TG), total cholesterol (TC), and low‐density lipoprotein (LDL‐C) levels and increase the serum high‐density lipoprotein (HDL‐C) level in NAFLD rats. In addition, TARAP treatment reduced expression of fatty acid synthetase (FAS), and acetyl‐CoA carboxylase (ACC) and upregulated the expression of carnitine palmitoyltransferase (CPT). Our results suggest that regulation of lipid metabolism may be a mechanism by which TARAP treats NAFLD.Keywords
Funding Information
- Natural Science Foundation of Fujian Province (2010J01191, 2010J01194)
- Natural Science Foundation of Fujian Province (2010J01191, 2010J01194)
This publication has 25 references indexed in Scilit:
- Hepatoprotection in a Rat Model of Acute Liver Damage Through Inhibition of CY2E1 Activity by Total Alkaloids Extracted From Rubus alceifolius PoirInternational Journal of Toxicology, 2011
- Natural products and drug discoveryEMBO Reports, 2009
- The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in miceLife Sciences, 2008
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered miceJournal of Clinical Investigation, 2008
- Non-alcoholic fatty liver disease: The mist gradually clearsJournal of Hepatology, 2008
- GI Epidemiology: nonalcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2007
- AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndromeNature Reviews Drug Discovery, 2004
- Mitochondrial β‐oxidationEuropean Journal of Biochemistry, 2004
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- The fatty acid chain elongation system of mammalian endoplasmic reticulumProgress in Lipid Research, 1992